Market Research Reports

  Liquid biopsy has a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics. A liquid biopsy helps physicians to analyze tumor-related information through a simple blood test. As researchers are generating data that have the potential to lead to unprecedented biological insight, albeit at the cost of the greater complexity of data analysis. Increasing investments in R&D of liquid biopsy products and services and various research fundings is one of the major opportunities in the global liquid biopsy market. The global  liquid biopsy market   was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine. Impact of COVID-19 The current global li

  The use of big data in healthcare for areas such as cardiovascular health can lead to savings worth billions of U.S. dollars every year. The data generated on a regular basis contain mostly unstructured formats, i.e., they are not arranged or curated according to a pre-existing data model and, therefore, pose challenges during analysis. The industry perception is that nearly 80% of the big data in healthcare is unstructured, rendering only about 20% eligible for analysis.   The global  big data in healthcare market  report highlights that the market was valued at $32,925.1 million in 2021 and is expected to reach $130,132.1 million by the end of 2031. The market is expected to grow at a CAGR of 13.96% during the forecast period 2022-2031. Market Segmentation Global Big Data in Healthcare Market (Components and Services) The global big data in healthcare market, based on components and services, has been segmented into hardware, software, and analytics services. Hardware in big data r

  The global spine X-ray and computed tomography market is anticipated to grow rapidly owing to the advancements in the medical imaging industry with the constant demand to provide cost-effective and high-quality solutions in a shorter time period.The market for spine X-ray and CT devices is rapidly growing, with an increasing number of X-rays and CT scans used in imaging of vertebral fractures, spinal infections, and spinal tumors, among others. Furthermore, the integration of AI in imaging has accelerated the growth of the market for factors such as rising healthcare costs, a lack of communication between physicians and patients, poor health conditions, a shortage of physicians and medical staff, and the rising prevalence of chronic health disorders.    The global   spine X-ray and computed tomography market  report highlights that the market was valued at $916.0 million in 2020 and is expected to reach $1,623.5 million by the end of 2030. The market is expected to grow at a CAGR of

  The shift of healthcare systems toward precision diagnostic and precision medicine will drive the adoption of lung cancer genomic testing facilitating informed treatment decision making and improving healthcare outcomes. Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market. The  lung cancer genomic testing medicine market  was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031. The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics. Impact of COVID-

  The next frontier of precision medicine, the global precision cardiology market showcases enormous potential to completely revolutionize the field of cardiovascular disease diagnosis, which is further anticipated to help stakeholders reduce the burden associated with these conditions. Significant strides in advancing sequencing technologies tools have facilitated an increasing number of cardiovascular genetic studies to be performed in the field of cardiology. Moreover, these studies have provided key insights into the underlying micro-environment, which is further harnessed by researchers, physicians, and market players to develop novel solutions for detecting cardiovascular conditions. To address this critical requirement, biotechnology companies are significantly investing in research and development (RD) to expand their respective precision cardiology portfolios for clinical and research applications. Our healthcare experts have found the  precision cardiology market  to be one o